Organicell, through its ZEO ScientifiX division, is at the forefront of regenerative therapeutics, focusing on the development of innovative biological therapies. The company specializes in autologous biologics, particularly its proprietary product, Patient Pure X™ (PPX™), which is derived from a patient's own blood. This concentrated formulation contains bioactive proteins and microRNAs that facilitate cell communication and play a crucial role in tissue healing, inflammation reduction, and overall cellular health. By harnessing the body's natural regenerative capabilities, Organicell aims to provide safe and effective solutions for various therapeutic and aesthetic applications.

The company emphasizes the significance of extracellular vesicles (EVs) in its therapeutic approach, highlighting their potential to target damaged cells and promote regeneration at the cellular level. Organicell's commitment to research and development in biologic medicine positions it as a leader in the field, with a focus on precision-based cellular therapies that are reshaping medical practices. By offering high-concentration products that complement aesthetic procedures, Organicell is dedicated to advancing the frontiers of regenerative medicine and enhancing patient outcomes through its innovative biologic solutions.

United States

Based in South Florida, ZEO ScientifiX™ is a publicly traded biotechnology company committed to the research, development and manufacture of new biologic medicine, with a focus on current and potential regenerative therapeutics. ZEO ScientifiX™ is the leading, fully integrated Biologic Medicine Company. Our mission is to transform regenerative medicine through the development of novel nano-technologies and to become the health care incubator for the next generation of biologic medicines.

ZEO ScientifiX (formerly Organicell Regenerative Medicine)

Company Details